

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 5/3/1930
Gender: Female
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

ERBB2 (HER2/neu) (HercepTest) with Interpretation by Immunohistochemistry, Tissue

ARUP test code 0049174

ERBB2 (HercepTest) by IHC

3+ Positive

This result has been reviewed and approved by [REDACTED] M.D.

INTERPRETIVE INFORMATION: HercepTest

Breast Tumors:

The result of the HercepTest by Dako (Agilent) is interpreted in a semi-quantitative manner. Test is FDA-approved for breast and gastric cancer only, and performed on formalin-fixed, paraffin-embedded tissue. Antibody clone is polyclonal and uses a proprietary detection system.

ARUP Laboratories uses the 2018 ASCO/CAP guidelines for interpretation of ERBB2 (HER2) protein expression in breast cancers fixed in formalin for 6-72 hours with a cold ischemic time of less than 1 hour. Tissue not meeting these requirements or tissue placed in decalcification solution should be interpreted with caution due to the likelihood of false negative results.

Positive cases are those with uniform, intense, complete circumferential membrane staining of more than 10 percent of invasive tumor cells (score 3+). Negative cases are defined as a) no staining observed, or incomplete membrane staining that is faint or barely perceptible and is less than or equal to 10 percent of the invasive tumor cells (score 0), or b) incomplete membrane staining that is faint or barely perceptible and is greater than 10 percent of the invasive tumor cells (score 1+). Equivocal cases are those with weak to moderate complete membrane staining observed in greater than 10 percent of tumor cells (score 2+). Other rare staining patterns may be considered equivocal. It is recommended that an Equivocal result be reflexed to another method of testing.

For more information refer to the ASCO/CAP guidelines found at www.jco.org.

Controls stained appropriately.

Percent of Cells/Circumferential 80

Intensity of Staining Strong

H=High, L=Low, *=Abnormal, C=Critical

Homogenous Pattern	Linear
Fixative Used	Formalin
Time from Bx to Fixative	<10 mins
Duration of Fixation	12-24 hrs
Sample Adequacy	Adequate
HER2 Reference Number	DSP23-43815 A1
HER2 Tissue Source	L Breast

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
ERBB2 (HercepTest) by IHC	23-324-156438	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Percent of Cells/Circumferential	23-324-156438	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Intensity of Staining	23-324-156438	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Homogenous Pattern	23-324-156438	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Fixative Used	23-324-156438	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Time from Bx to Fixative	23-324-156438	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Duration of Fixation	23-324-156438	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Sample Adequacy	23-324-156438	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
HER2 Reference Number	23-324-156438	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
HER2 Tissue Source	23-324-156438	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at: